OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases underserved by existing therapies. The company employs a structure based drug design platform that integrates medicinal chemistry, x ray crystallography and computational chemistry to design small molecule inhibitors that selectively bind mutant forms of proteins while…
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases underserved by existing therapies. The company employs a structure based drug design platform that integrates medicinal chemistry, x ray crystallography and computational chemistry to design small molecule inhibitors that selectively bind mutant forms of proteins while sparing the wild type counterparts. Its lead product candidate, OKI-219, is an orally administered selective inhibitor of the PI3Kα H1047R mutation, demonstrating approximately 80 fold selectivity for the mutant enzyme over the wild type form. OKI-219 is being evaluated in a Phase 1 open label multi arm clinical trial known as PIKture-01, which includes monotherapy and combination arms in patients with solid tumors harboring the PI3Kα H1047R mutation. The company’s strategy is to initially develop OKI-219 for advanced breast cancer subsets defined by hormone receptor status and HER2 expression, with the goal of establishing it as a backbone therapy in combination with standard of care agents.
OnKure Therapeutics, Inc. does not yet generate revenue from product sales because its therapeutic candidates remain in clinical development and have not received regulatory approval. The company finances its research and development activities through external funding sources, which may include equity offerings, private placements and potential collaborations. As a pre revenue biotechnology firm, its financial statements reflect operating expenses related to drug discovery, preclinical studies and clinical trial execution.
OnKure Therapeutics competes in the growing field of PI3K targeted therapies, where approved agents such as alpelisib (Piqray) from Novartis, capivasertib (Truqap) from AstraZeneca, and inavolisib (Itovebi) from Genentech are used in combination with endocrine therapies for patients with PI3Kα mutated breast cancer. These existing inhibitors often lack sufficient selectivity between mutant and wild type PI3Kα, leading to on target toxicities such as hyperglycemia, rash and gastrointestinal effects that can limit dosing and clinical benefit. OkI-219 aims to overcome this limitation by showing approximately 80 fold selectivity for the mutant PI3Kα H1047R form over the wild type enzyme, a profile supported by preclinical binding studies and early clinical data that indicate minimal impact on wild type signaling. In addition to its selectivity, preclinical models suggest that OKI-219 penetrates the blood brain barrier, raising the possibility of activity against central nervous system metastases. The company is also advancing a pan mutant PI3Kα inhibitor program designed to target the most common mutations including H1047R, E545K and E542K, with plans to announce a development candidate in the first quarter of 2026. Furthermore, OkI-219 is being explored for potential use in vascular malformations driven by PI3Kα pathway mutations, broadening the therapeutic scope beyond oncology. These scientific and clinical attributes position OnKure Therapeutics as a differentiated player focused on precision inhibition with the aim of improving safety and efficacy for patients with PI3Kα driven diseases.
OnKure Therapeutics intends to serve patients with PI3Kα mutated cancers, with an initial focus on breast cancer subtypes that harbor the H1047R mutation, including hormone receptor positive HER2 negative and hormone receptor negative HER2 positive populations. The therapeutic candidate OKI-219 is being evaluated for use in advanced or metastatic disease, either as monotherapy or in combination with agents such as fulvestrant, CDK4/6 inhibitors and other endocrine therapies. The company envisions its medicines being prescribed by oncologists and administered in hospital oncology departments, outpatient cancer clinics and specialized treatment centers that manage solid tumor patients. While the filing does not disclose specific customer names, the target audience comprises individuals diagnosed with PI3Kα altered tumors and the healthcare providers responsible for their cancer care.